Dimitris L. Kontoyiannis

Dimitris L. Kontoyiannis

Auto-generated profile, based on publicly available information

Dimitris L. Kontoyiannis

Biomedical Sciences Research Centre “Alexander Fleming”, Institute of Fundamental Biomedical Research, Vari, Greece

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1999 in Immunity
Verified
Journal Article
Closed access
DKDimitris Kontoyiannis
Dimitris Kontoyiannis
MPManolis Pasparakis
Manolis Pasparakis
TPTheresa T Pizarro
Theresa T Pizarro
FCFabio Cominelli
Fabio Cominelli
GKGeorge Kollias
George Kollias

1 December 2000 in Cell
Verified
Journal Article
Closed access
CDCalin D Dumitru
Calin D Dumitru
JCJeffrey D Ceci
Jeffrey D Ceci
CTChristos Tsatsanis
Christos Tsatsanis
DKDimitris Kontoyiannis
Dimitris Kontoyiannis
KSKonstantinos Stamatakis
Konstantinos Stamatakis
PTPhilip N Tsichlis
Philip N Tsichlis

4 February 2008 in Journal of Experimental Medicine
Verified
Journal Article
Open access
MAMaria ARMAKA
Maria ARMAKA
MAMaria Apostolaki
Maria Apostolaki
PJPeggy Jacques
Peggy Jacques
DKDimitris L. Kontoyiannis
Dimitris L. Kontoyiannis
DEDirk Elewaut
Dirk Elewaut
GKGeorge Kollias
George Kollias
Tumor necrosis factor (TNF) is key to the pathogenesis of various arthritic diseases and inflammatory bowel disease (IBD). Anti-TNF therapies have proved successful in the clinical treatment of these diseases, but a mechanistic understanding of TNF function is still lacking. We have investigated early cellular mechanisms of TNF function in these diseases using an established TNF transgenic model, which develops a spondyloarthritis-like disease characterized by peripheral joint arthritis, sacroiliitis, enthesitis, and Crohn's-like IBD. Bone marrow grafting experiments demonstrated that development of arthritis requires TNF receptor I (TNFRI) expression in the radiation-resistant compartment, which is also known to be a sufficient target of TNF in the development of Crohn's-like IBD in the same model. Early activation of synovial fibroblasts and intestinal myofibroblasts could also be demonstrated by perturbed expression of matrix metalloproteases and their inhibitors. Notably, selective Cre/loxP-mediated TNFRI expression in mesenchymal cells resulted in a fully arthritic–spondyloarthritic and intestinal phenotype, indicating that mesenchymal cells are primary and sufficient targets of TNF in these pathologies. Our results offer a novel mechanistic perspective for TNF function in gut and joint pathologies and indicate early common cellular pathways that may also explain the often observed synovial–gut axis in human disease.

1 February 2002 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ANArmin Neininger
Armin Neininger
DKDimitris Kontoyiannis
Dimitris Kontoyiannis
AKAlexey Kotlyarov
Alexey Kotlyarov
RWReinhard Winzen
Reinhard Winzen
RERolf Eckert
Rolf Eckert
MGMatthias Gaestel
Matthias Gaestel
We demonstrate that lipopolysaccharide-induced tumor necrosis factor (TNF) biosynthesis becomes independent of MAPKAP kinase 2 (MK2) when the AU-rich element (ARE) of the TNF gene is deleted. In spleen cells and macrophages where TNF biosynthesis is restored as a result of this deletion, interleukin (IL)-6 biosynthesis is still dependent on MK2. In MK2-deficient macrophages the half-life of IL-6 mRNA is reduced more than 10-fold, whereas the half-life of TNF mRNA is only weakly decreased. It is shown that the stability of a reporter mRNA carrying the AU-rich 3′-untranslated region (3′-UTR) of IL-6 is increased by MK2. The data provide in vivo evidence that the AU-rich 3′-UTRs of TNF and IL-6 are downstream to MK2 signaling and make MK2 an essential component of mechanisms that regulate biosynthesis of IL-6 at the levels of mRNA stability, and of TNF mainly through TNF-ARE-dependent translational control.

9 December 2002 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
DKDimitris Kontoyiannis
Dimitris Kontoyiannis
GBGeorge Boulougouris
George Boulougouris
MMMenelaos Manoloukos
Menelaos Manoloukos
MAMaria ARMAKA
Maria ARMAKA
MAMaria Apostolaki
Maria Apostolaki
GKGeorge Kollias
George Kollias
Recent clinical evidence demonstrated the importance of tumor necrosis factor (TNF) in the development of Crohn9s disease. A mouse model for this pathology has previously been established by engineering defects in the translational control of TNF mRNA (TnfΔAREmouse). Here, we show that development of intestinal pathology in this model depends on Th1-like cytokines such as interleukin 12 and interferon γ and requires the function of CD8+ T lymphocytes. Tissue-specific activation of the mutant TNF allele by Cre/loxP-mediated recombination indicated that either myeloid- or T cell–derived TNF can exhibit full pathogenic capacity. Moreover, reciprocal bone marrow transplantation experiments using TNF receptor–deficient mice revealed that TNF signals are equally pathogenic when directed independently to either bone marrow–derived or tissue stroma cell targets. Interestingly, TNF-mediated intestinal pathology was exacerbated in the absence of MAPKAP kinase 2, yet strongly attenuated in a Cot/Tpl2 or JNK2 kinase–deficient genetic background. Our data establish the existence of redundant cellular pathways operating downstream of TNF in inflammatory bowel disease, and demonstrate the therapeutic potential of selective kinase blockade in TNF-mediated intestinal pathology.